Loading stockRelated stocks: Instruments For Meas & Testing of Electricity & Elec Signals
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Transcat, Inc. ( Transcat , the Company, we or us ) is a leading provider of accredited calibration services, cost control and optimization services, and distribution and rental of value-added professional grade handheld test, measurement, and control instrumentation. We are focused on providing services and products to highly regulated industries, particularly the life science industry, which …
$87.90
$1.88 (-2.09%)
EOD Jul 17, 2026
Operating margin is thin at 4.00%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 19.2%, still solid. Margins contracted 2.4pp, which offsets some of the top-line progress.
At 154x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 24% versus the prior year, cash generation momentum has weakened.
154.2x earnings, 42.2x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$332M
▲ +19.2% YoY
Net Income (TTM)
$5M
▼ -63.0% YoY
Op. Margin
4.00%
▼ -2.4pp YoY
ROIC
2.74%
▼ -2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$20M
▼ -24.2% YoY
Op. Cash Flow (TTM)
$35M
▼ -10.6% YoY
Net Debt
$129M
Cash & Equiv.
$5M
5Y CAGR: +13.9%
5Y CAGR: +2.8%
Continue Research
At a P/E of 154.2 and a price-to-free-cash-flow of 42.2, Transcat (TRNS) trades around a two-stage DCF intrinsic value of about $91.50 per share, so at $87.90 the stock looks around fair value (4.1% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Transcat scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $91.50 per share for TRNS, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $68.63. At today's $87.90, that puts the stock about 4.1% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Transcat scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 4.0% operating margin and a 2.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. TRNS currently trades around its estimated intrinsic value and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.